A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities
- PMID: 40730794
- PMCID: PMC12307612
- DOI: 10.1038/s41598-025-04918-0
A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities
Abstract
With limited treatments for carbapenem-resistant Klebsiella pneumoniae (CRKp), curtailing transmission is critical. We applied a network analysis using epidemiological admission data and bacterial genetics to characterize CRKp spread among patients in 16 acute care hospitals linked to 217 other healthcare facilities in the United States. Patients with diagnosed CRKp infection were selected from the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE-1), a prospective, observational study conducted from 12/2011 to 6/2016. A network analysis was performed using epidemiological admission data and bacterial genetics to characterize putative CRKp transmission among patients across various healthcare facilities and the community. Overall, 347/526 patients (66%) had a putative transmission link to at least one other patient within the network. Most transmission chains were small (i.e., between 2 patients); however, the largest included 172 patients diagnosed over 1575 days. One-third of patients shared a genetically similar CRKp isolate with another patient but had no observed epidemiological linkages at any healthcare location. Patients with CRKp are part of extensive regional networks involving a large number of non-hospital healthcare settings such as skilled nursing facilities. Thus, controlling spread necessitates integrated surveillance and control initiatives at regional and national levels in addition to institution-specific approaches.
Keywords: Antimicrobial resistance; Bacterial typing; Enterobacterales; Infection control; Network analysis; Nosocomial infections.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: DvD reports grants and contracts from the NIH, Merck, and Shinogi, paid to his institution, outside of the published work; consultancy for Actavis, Tetraphase. Sanofi-Pasteur. MedImmune, Astellas, Merck, Allergan, T2Biosystems, Roche, Achaogen, Neumedicine, Shionogi, Pfizer, Entasis, Qpex, Wellspring, Karius, and Utility paid directly to him; honoraria from Pfizer; and an editor’s stipend from the British Society for Antimicrobial Chemotherapy (BSAC). RRW is a stockholder and employee of CVS Health; has received a grant from Allergan; and has been a paid consultant for bioMerieux outside of the published work. YD reports grants from the NIH, AMED, Shionogi and Entasis, paid to his institution, outside of the published work; consultancy for Gilead, Shionogi, GSK, Moderna, Pfizer, AbbVie, paid directly to him; and honoraria from Shionogi. KSK reports consultancy for Merck, Abbvie, Shiognogi, Carb-X, GSK, Xellia. RAB reports grants from Merck, Entasis, and Shionogi outside of the published work. The remaining authors declare no conflicts of interest.
Figures


References
-
- Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services (2019).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources